Epidemiology of sarcoidosis

Thomeer, Michiel; Demedts, Maurice; Wuyts, Wim; Oost-Limburg, Ziekenhuis

doi:10.1183/1025448x.00032002

Cited by 27 publications

(38 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although possible at all ages, higher occurrence is observed between 25 and 40 years in both genders, at least in Scandinavian countries and Japan, and a second peak of incidence has been reported in women over 50 years of age in some published studies. The incidence of sarcoidosis is remarkably low before 15 years (1/100,000) and extremely rare before 4 years of age (0.06/100,000) (10,11). The clinical expression and severity of sarcoidosis depend on epidemiological factors.…”

Section: Epidemiologymentioning

confidence: 97%

See 1 more Smart Citation

Sarcoidosis and its otolaryngological implications

Mrówka-Kata¹,

Kata

Lange

et al. 2010

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

Section: Epidemiologymentioning

confidence: 97%

“…In blacks, the disease is more likely to be disseminated, showing a higher frequency of ophthalmological, cutaneous, hepatic and lymphatic localisations, and its course in undeniably more severe. [7,10,11].…”

Section: Epidemiologymentioning

confidence: 98%

Sarcoidosis and its otolaryngological implications

Mrówka-Kata¹,

Kata

Lange

et al. 2010

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…Proportions per 100,000 population ranged from 0.1 to 64 [14][15][16]. Available individual country prevalences were used for the UK [17], Israel [18], Iceland [19], Spain (pulmonary sarcoidosis only) [20], Greece [21], Switzerland [22], Japan [23] and the USA [24].…”

Section: Methodsmentioning

confidence: 99%

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Pleuvry²,

2012

View full text Add to dashboard Cite

Chronic pulmonary aspergillosis (CPA) may complicate pulmonary sarcoidosis. We re-estimated the global burden of sarcoidosis and the burden of CPA complicating sarcoidosis.We searched the literature and reference lists of retrieved papers to identify all published sarcoidosis incidence and prevalence data. We estimated the frequency of CPA from 11 papers relating to .3,000 patients with sarcoidosis to derive CPA patient numbers. We applied an annual attrition rate of 15% (range 10-25%) to estimate the global burden of CPA.We estimate that the annual incidence of sarcoidosis is 344,000 patients worldwide and the prevalence is ,1,238,000 cases, distributed as follows: 165,979 in Europe, 224,000 in the Americas, 492,892 in Africa, 80,023 in the Eastern Mediterranean, 41,660 in the West Pacific and 234,010 in Southeast Asia. CPA complicates sarcoidosis in 3-12% of cases. Using a 6% frequency, we estimate a global burden of 71,907 (range 35,954-143,815 (3-12%)) CPA cases complicating sarcoidosis, with 24% and 37% of cases estimated to be present in the Americas and Africa, because of the higher incidence of sarcoidosis in black people.As CPA responds to long-term antifungal therapy, which may prevent life-threatening haemoptysis, screening periodically for CPA in those with pulmonary sarcoidosis may be important, especially in patients requiring corticosteroid therapy.

show abstract

“…Numerous aetiological agents have been incriminated, both infective and noninfective [3]. Noninfective agents have been implicated because of their epidemiological association [4], but these implications have not stood the test of time [5]. Currently, the focus is on infective agents, and the two strongest contenders are Propionibacterium and Mycobacterium [6].…”

mentioning

confidence: 99%

Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis

Gupta¹,

Agarwal²,

An³

et al. 2007

European Respiratory Journal

183

120

View full text Add to dashboard Cite

The aetiology of sarcoidosis is currently unknown. Due to the clinical and histological similarities between sarcoidosis and tuberculosis, the role of mycobacteria has been repeatedly investigated as an aetiological agent for sarcoidosis. The current meta-analysis aimed to evaluate the available molecular evidence on the possible role of mycobacteria in the development of sarcoidosis.The MEDLINE, EMBASE, CINAHL, DARE and CENTRAL databases were searched for relevant studies published from 1980 to 2006, and studies evaluating the presence of mycobacteria using molecular techniques in biological samples of patients with sarcoidosis were included in the current analysis. The 95% confidence intervals (CI) were calculated for the expected proportion (of individual studies); the data was then pooled to obtain a summary success rate with 95% CI. The odds ratio (95% CI) was also calculated in order to assess the presence of mycobacteria in samples of patients with sarcoidosis versus those from nonsarcoidosis control samples.The database search yielded 31 studies. All studies used polymerase chain reaction for nucleic acid amplification followed by identification of nucleic acid sequences specific for different types of mycobacteria. Overall, 231 out of the 874 patients were positive for mycobacteria with a positive signal rate of 26.4 (23.6-29.5%), and the odds of finding mycobacteria in samples of patients with sarcoidosis versus controls were 9.67 (4.56-20.5%) using the random effects model and 19. 49 (11.21-35.54%) using the exact method. There was methodological and statistical heterogeneity and evidence of publication bias.The results of the current study illustrate a demonstrable mycobacterial presence in sarcoidosis lesions suggesting an association between mycobacteria and some cases of sarcoidosis. To avoid methodological diversity, larger multicentre trials with a central laboratory for sample testing should be designed.

show abstract

Epidemiology of sarcoidosis

Cited by 27 publications

References 34 publications

Sarcoidosis and its otolaryngological implications

Sarcoidosis and its otolaryngological implications

Global burden of chronic pulmonary aspergillosis complicating sarcoidosis

Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis

Contact Info

Product

Resources

About